 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Axonics Modulation Technologies, Inc. (AXNX) is a medical technology company.
The firm engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally.
The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention.
Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction.
The Company's implantable devices designed to eliminate incontinence already gives the company at least 20% and perhaps more than 40% of its market, according to analysts. This for a product that the U.S. Food and Drug Administration approved last October. Shares have formed a bullish "cup and handle" and are on the cusp of breaking out of their bullish formation.
Entry Point: $45.00
Trading Range: $15.25 - $46.15
Stop Loss: $42.50
Target Price: $49.50
AXNX closed at $49.50
